| 产品描述： | AGI-5198 (IDH-C35) is a potent and selective mutant IDH1R132H inhibitor with an IC50 of 0.07 μM. |
| 靶点： |
IDH1;Dehydrogenase;IsocitrateDehydrogenase(IDH) |
| 体内研究： |
AGI-5198 (450 mg/kg, p.o.) causes 50 to 60% growth inhibition of the tumor growth from human glioma xenografts. Tumors from AGI-5198- treated mice show reduced staining with an antibody against the Ki-67 protein. AGI-5198 does not affect the growth of IDH1 wild-type glioma xenografts |
| 参考文献： |
1. Rohle D, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013 May 3;340(6132):626-30. 2. Molenaar RJ, et al. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Res. 2015 Nov 15;75(22):4790-802. |
| 溶解性： |
DMF : ≥ 50 mg/mL (108.09 mM) DMSO : 20.83 mg/mL (45.03 mM; Need ultrasonic) |
| 保存条件： |
-20℃ |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.162 ml |
10.809 ml |
21.619 ml |
| 5 mM |
0.432 ml |
2.162 ml |
4.324 ml |
| 10 mM |
0.216 ml |
1.081 ml |
2.162 ml |
| 50 mM |
0.043 ml |
0.216 ml |
0.432 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京